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Recent development of molecular tools for pathogen 
detection introduced the possibility of early targeted 
antimicrobial treatment that, in turn, may improve the 
outcome of patients with sepsis [1].
We retrospectively evaluated 54 results of the SeptiFast 
test from patients with solid malignancy admitted to the 
ICU between June 2009 and August 2011. Specimens 
from suspected bloodstream infection were analyzed 
using LightCycler SeptiFast (Roche Molecular Diagnostics 
[AU Query: Provide city, state and country]) according 
to the manufacturer’s instruction and evaluated in 
comparison with blood culture results obtained from 
blood sampled no longer than 24  hours before or after 
sampling for SeptiFast. Blood culturing and identiﬁ cation 
were performed according to the routine diagnostic 
procedures. Th e total number of blood cultures analyzed 
was 85, and ﬁ nding a microorganism by either of the two 
tests was evaluated as positive [AU Query: Conﬁ rm 
sentence is OK]. Consistently, negative results from 
SeptiFast and blood culture were obtained in 21 (39%) 
cases.
To assess the true positivity of both microbiological 
methods, discrepant cases were evaluated in the context 
of clinical and laboratory ﬁ ndings by two independent 
physicians experienced in critical care (Figure  1). Th e 
clinically relevant presence of a pathogen detected by 
blood culture but not by SeptiFast was recorded for 
Klebsiella pneumoniae/oxytoca, and in both cases the 
presence of another member of Enterobacteriaceae was 
reported by SeptiFast, Escherichia coli and Enterobacter 
cloacae/aerogenes – thus misidentiﬁ cation of strains with 
atypical phenotype cannot be excluded [3] [AU Query: 
Conﬁ rm sentence is OK]. Our results also show that 
SeptiFast is more eﬃ  cient in detection of clinically 
relevant infection by E. coli and Pseudomonas aeruginosa.
Th e turnaround time for blood culture analysis is 24 to 
48 hours. Th e workﬂ ow in our laboratory allows SeptiFast 
analysis every working day during a day shift. In such 
conditions, the turnaround time of SeptiFast results for 
samples delivered to the laboratory on a workday 
between 7:00 and 14:00  hours was as follows: 100% 
samples, 10  hours; 97%, 8  hours; 59%, 6  hours [AU 
Query: Conﬁ rm sentence is OK]. Th e average turn-
around time for tests performed with manual DNA 
isolation was 6 hours 11 minutes; by implementation of 
automated isolation of DNA using the MagNA Pure 
Compact System [4], the mean turnaround time was 
shortened to 5  hours 17  minutes [AU Query: Conﬁ rm 
sentence is OK].
In conclusion, detection of pathogen by the LightCycler 
SeptiFast system is generally not inferior to the results 
from blood culture. Th e added value of multiplex DNA 
ampliﬁ cation-based pathogen detection is the shorter 
turnaround time and probably the increased true 
sensitivity of detection of certain pathogens [AU Query: 
Conﬁ rm sentence is OK]. Moreover, the subset of 
pathogen detection is required in the background of 
antibiotic administration; in such conditions, cultivation-
independent methods are of clear beneﬁ t [5] [AU Query: 
Conﬁ rm sentence is OK].
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Figure 1. Scheme summarizing detection of pathogens together with clinical evaluation of discrepant fi ndings. Totally 47 pathogens were 
detected in 29 SeptiFast (SF) and/or 43 blood culture (BC) samples. From 20 pathogens listed on the SF menu [2], nine were detected in the present 
study and all pathogens detected by blood culture were on the SF menu, 18 microorganisms were detected by both BC and SF, 12 by BC only, and 
17 by SF only. The clinical evaluation is as follows: each pathogen detected by either method was classifi ed as possible infection (based on clinical 
data; for example, benefi t from antimicrobial therapy), as probable infection (based on clinical data and cultivation of the pathogen from other site), 
as highly probable infection (based on clinical data and presence of the pathogen in blood within the relevant time window), as unlike infection 
(for example, contamination) or as undetermined. To obtain orientation in false positive and false negative results in pathogen detection by SF and 
cultivation, we assigned a score value to each positive classifi cation as follows: possible infection (score 2), probable infection (score 3), and highly 
probable infection (score 4). Black boxes represent summary of cases when pathogen was detected by both methods, SF and BC. Blue boxes right 
of concordant events show detection by BC only, and red objects left of black squares represent events of pathogen detection by SF only. Empty 
boxes, cases evaluated by both ICU experts as unlike infection; unclear, cases evaluated by ICU experts discrepantly (for example, unlike vs. possible 
or probable infection). The size of fi lled objects together with abbreviated classifi cation describe the evaluation of ICU experts for each case: h.pr., 
highly probable infection; pr., probable infection; po., possible infection. Coagulase-negative staphylococci (CoNS) were detected far more often 
by BC than SF, probably as a result of contamination of blood culture sample by staphylococci from normal skin fl ora. Regarding CoNS, SF is able to 
refl ect the amount of CoNS DNA template; if its level is below the discrimination threshold (crossing point (CP) value of amplifi cation growth curve 
>20), the result is reported as negative. In this context, we retrospectively evaluated all SF raw data fi les for the CoNS amplifi cation curve and its CP. 
The CoNS curve with CP >20 was present in 15 out of 44 (34%) SF staphylococci-negative with a lowest CP of 21.4, supporting the necessity for the 
discrimination threshold in the SF evaluation algorithm for commensal bacteria. [AU Query: Carefully check and confi rm caption is OK]
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